drugset / Trial / NCT02313922

Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate

NCT02313922

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate whether etanercept combined with methotrexate are superiority than etanercept as monotherapy in the treatment of chinese severe plaque psoriasis. A phase IV, multicenter, randomized, double-blind, controlled trial was conducted.The primary outcome was Change from baseline in plaque psoriasis as assessed by PASI (psoriasis area and severity index) response or PASI75 (a patient that has an improvement from baseline PASI of at least 75%)

Timeline

Start
2014-11
Primary completion
2018-08
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule
Background Etanercept Protein / enzyme biologic

Indications